Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the “Notification Letter”)
Angle PLC (AIM:AGL) Spread of breast cancer accelerates during sleep
CTCs, CTC clusters and CTC-WBC clusters harvested using Parsortix were more numerous and more aggressive in initiating metastasis during sleep
Midatech Pharma PLC (AIM:MTPH) MTX110 Development for the Treatment of Glioma
Orphan Designation Granted by EMA to MTX110 Development for the Treatment of Glioma
Midatech Pharma PLC (AIM:MTPH) Proposed New Chairman – MTX110 Study to be Presented
Midatech Pharma (MTPH), an R&D biotechnology company, said that Rolf Stahel, Chairman and non-executive director, intends to retire after the company’s AGM on 20 June 2022.
Angle PLC (AIM:AGL) Molecular characterisation of CTCs
PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA
Angle PLC (AIM:AGL) receives FDA clearance for Parsortix
ANGLE ACHIEVES WORLD FIRST WITH FDA CLEARANCE FOR ITS PARSORTIX SYSTEM
Angle PLC (AIM:AGL) Identifying therapeutic targets in TNBC patients
PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER